透過您的圖書館登入
IP:52.14.22.250
  • 期刊

Etoposide (VP-16)誘導p53缺失非小細胞肺癌細胞的凋亡

Etoposide (VP-16)-induced Apoptosis in Human Non-small Cell Lung Cancer Cells Lacking Endogenous p53

若您是本文的作者,可授權文章由華藝線上圖書館中協助推廣。

摘要


VP-16是一種廣泛被使用的抗癌藥劑,其主要的作用機制是抑制topoisomerase IIα的活性,阻斷DNA的複製,造成腫瘤細胞生長停滯甚至死亡,以達到消滅腫瘤的目的。本研究發現低劑量(5 µM) VP-16可以誘導p53基因缺失的非小細胞肺癌細胞株(NSCLC) H1299的細胞凋亡(apoptosis)。實驗證明VP-16誘導H1299在凋亡的過程中,caspase酵素群扮演相當重要的角色,進一步的分析也發現caspase的活化與凋亡的過程密切關聯(caspase-dependent)。綜合而論,低劑量VP-16誘導p53基因缺失H1299細胞的凋亡模式中,caspase-9可能參與細胞凋亡早期誘導作用,而caspase-7則與凋亡晚期的DNA片段化(fragmentation)有關,試驗中並得知caspase-7抑制劑無法阻止細胞凋亡,推論VP-6除了誘導caspase活化所引起細胞凋亡,同時也活化其他因子參與凋亡的過程。

並列摘要


VP-16 (etoposide), an inhibitor of topoisomerase IIα, was widely used for cancer therapy. We found low dosage of VP-16 causes apoptosis in cancer cells without functional p53. In this work, we have identified that caspases were responsible for the progression of apoptosis in VP-16-induced H1299 cells lacking endogenous p53. Further study showed that apoptosis effectors caspase-9 and caspase-7 were activated prior to apoptosis. This work also demonstrated that VP-16-induced apoptosis in human non-small cell lung cancer cells is independent of p53 status.

延伸閱讀